In cases of larger polyps or more severe inflammation ... and the formation of mucoceles. Treatment includes a combination of steroids, nasal rinses, and in more severe cases, surgery.

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

Nasal polyps are linked to chronic inflammation from asthma, allergies, or infections. Medications can shrink nasal polyps. Surgery is often needed to remove them, but they can grow back unless ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

It is often categorized into two main types: CRS with nasal polyps (CRSwNP ... effectiveness of new treatment options, particularly biologics, which target specific inflammatory pathways ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

Researchers identify a pathogenic subset of CD8+ memory T-cells that promote airway tissue inflammation and recurrent respiratory diseases.